Search CTL/CD8+ T-Cell Epitope Database

Found 5 matching records:

Displaying record number 58642

Download this epitope record as JSON.

HXB2 Location	Gag(77-85) p17(77-85) DNA(1018..1044)	Gag Epitope Map
Author Location	Gag(77-85)
Epitope	SLYNTVATL	Epitope Alignment
Epitope Name	Gag77-85
Subtype	B
Species (MHC/HLA)	human(A*02:01)
Immunogen	peptide-HLA interaction
Country	United States
Experimental methods	Chromium-release assay
Keywords	enhancing activity

Notes

• Since HIV-1 infected peripheral dendritic cells (DCs) are functionally impaired in their role as antigen presenting cells (APCs), novel CTL responses in an asymptomatic HIV-patient were primed by using blood-derived DCs from healthy donors as APCs instead. Both epitope peptides and endogenously processed epitope antigen were now recognizable.
• CTL from an HLA-A*0201 positive subject reacted to a previously characterized peptide SLYNTVATL.

References

Dupuis1997 M. Dupuis, M. V. Peshwa, C. Benike, S.K> Kundu, E. G. Engleman, W. C. Van Schooten, and T. C. Merigan. Allogeneic Dendritic Cell Induction of HIV-Specific Cytotoxic T Lymphocyte Responses from T Cells of HIV Type 1-Infected and Uninfected Individuals. AIDS Res. Hum. Retroviruses, 13:33-39, 1997. The potential benefit of T cell-based vaccination for HIV-1 infection remains to be determined. Cytotoxic T lymphocytes (CTLs) appear to clear substantial populations of HIV-1 virus in vivo, although CTL activity may contribute to the decline in CD4+ T cell count observed in the course of the disease. To investigate further the role of specific CTL responses in the control of HIV-1 replication, we raised primary CTL lines against a panel of conserved HIV-1 epitopes using blood-derived dendritic cells as antigen-presenting cells (APCs). Specific primary human CTL responses were induced against HLA-A*0201-restricted peptides with dendritic cells from HIV-1-seronegative donors. This method of immunization elicited cytotoxic activities capable of recognizing endogenously processed antigen. The CTL induction protocol was extended in order to explore the capacity of HLA-matched allogeneic dendritic cells to evoke novel CTL responses in T cells from an HIV-seropositive asymptomatic individual. Allogeneic peptide-pulsed dendritic cells from a healthy sibling were capable of eliciting a CTL response directed against an HIV epitope (env814: SLLNATDIAV) that was initially not detected in the CTL effector population of the HIV-1- infected patient. The possibility of manipulating CTL specificity directed against multiple conserved HIV-1 epitopes represents a significant step in the evaluation of T cell-based vaccination for treatment of disease. PubMed ID: 8989425. Show all entries for this paper.

Displaying record number 58640

Download this epitope record as JSON.

HXB2 Location	Pol(464-472) RT(309-317) DNA(3474..3500)	Pol Epitope Map
Author Location	Pol(464-472)
Epitope	ILKEPVHGV	Epitope Alignment
Epitope Name	Pol464-472
Subtype	B
Species (MHC/HLA)	human(A*02:01)
Immunogen	peptide-HLA interaction
Country	United States
Experimental methods	Chromium-release assay
Keywords	enhancing activity

Notes

• Since HIV-1 infected peripheral dendritic cells (DCs) are functionally impaired in their role as antigen presenting cells (APCs), novel CTL responses in an asymptomatic HIV-patient were primed by using blood-derived DCs from healthy donors as APCs instead. Both epitope peptides and endogenously processed epitope antigen were now recognizable.
• CTL from an HLA-A*0201 positive subject reacted to previously characterized peptide ILKEPVHGV.

References

Dupuis1997 M. Dupuis, M. V. Peshwa, C. Benike, S.K> Kundu, E. G. Engleman, W. C. Van Schooten, and T. C. Merigan. Allogeneic Dendritic Cell Induction of HIV-Specific Cytotoxic T Lymphocyte Responses from T Cells of HIV Type 1-Infected and Uninfected Individuals. AIDS Res. Hum. Retroviruses, 13:33-39, 1997. The potential benefit of T cell-based vaccination for HIV-1 infection remains to be determined. Cytotoxic T lymphocytes (CTLs) appear to clear substantial populations of HIV-1 virus in vivo, although CTL activity may contribute to the decline in CD4+ T cell count observed in the course of the disease. To investigate further the role of specific CTL responses in the control of HIV-1 replication, we raised primary CTL lines against a panel of conserved HIV-1 epitopes using blood-derived dendritic cells as antigen-presenting cells (APCs). Specific primary human CTL responses were induced against HLA-A*0201-restricted peptides with dendritic cells from HIV-1-seronegative donors. This method of immunization elicited cytotoxic activities capable of recognizing endogenously processed antigen. The CTL induction protocol was extended in order to explore the capacity of HLA-matched allogeneic dendritic cells to evoke novel CTL responses in T cells from an HIV-seropositive asymptomatic individual. Allogeneic peptide-pulsed dendritic cells from a healthy sibling were capable of eliciting a CTL response directed against an HIV epitope (env814: SLLNATDIAV) that was initially not detected in the CTL effector population of the HIV-1- infected patient. The possibility of manipulating CTL specificity directed against multiple conserved HIV-1 epitopes represents a significant step in the evaluation of T cell-based vaccination for treatment of disease. PubMed ID: 8989425. Show all entries for this paper.

Displaying record number 58641

Download this epitope record as JSON.

HXB2 Location	Pol(956-965) Integrase(241-250) DNA(4950..4979)	Pol Epitope Map
Author Location	Pol(956-964)
Epitope	LLWKGEGAVV	Epitope Alignment
Epitope Name	Pol956-964
Subtype	B
Species (MHC/HLA)	human(A*02:01)
Immunogen	peptide-HLA interaction
Country	United States
Experimental methods	Chromium-release assay
Keywords	enhancing activity

Notes

• Since HIV-1 infected peripheral dendritic cells (DCs) are functionally impaired in their role as antigen presenting cells (APCs), novel CTL responses in an asymptomatic HIV-patient were primed by using blood-derived DCs from healthy donors as APCs instead. Both epitope peptides and endogenously processed epitope antigen were now recognizable.
• CTL from an HLA-A*0201 positive subject did not react to a previously characterized peptide LLWKGEGAVV.

References

Dupuis1997 M. Dupuis, M. V. Peshwa, C. Benike, S.K> Kundu, E. G. Engleman, W. C. Van Schooten, and T. C. Merigan. Allogeneic Dendritic Cell Induction of HIV-Specific Cytotoxic T Lymphocyte Responses from T Cells of HIV Type 1-Infected and Uninfected Individuals. AIDS Res. Hum. Retroviruses, 13:33-39, 1997. The potential benefit of T cell-based vaccination for HIV-1 infection remains to be determined. Cytotoxic T lymphocytes (CTLs) appear to clear substantial populations of HIV-1 virus in vivo, although CTL activity may contribute to the decline in CD4+ T cell count observed in the course of the disease. To investigate further the role of specific CTL responses in the control of HIV-1 replication, we raised primary CTL lines against a panel of conserved HIV-1 epitopes using blood-derived dendritic cells as antigen-presenting cells (APCs). Specific primary human CTL responses were induced against HLA-A*0201-restricted peptides with dendritic cells from HIV-1-seronegative donors. This method of immunization elicited cytotoxic activities capable of recognizing endogenously processed antigen. The CTL induction protocol was extended in order to explore the capacity of HLA-matched allogeneic dendritic cells to evoke novel CTL responses in T cells from an HIV-seropositive asymptomatic individual. Allogeneic peptide-pulsed dendritic cells from a healthy sibling were capable of eliciting a CTL response directed against an HIV epitope (env814: SLLNATDIAV) that was initially not detected in the CTL effector population of the HIV-1- infected patient. The possibility of manipulating CTL specificity directed against multiple conserved HIV-1 epitopes represents a significant step in the evaluation of T cell-based vaccination for treatment of disease. PubMed ID: 8989425. Show all entries for this paper.

Displaying record number 58638

Download this epitope record as JSON.

HXB2 Location	gp160(121-129) gp120(121-129) DNA(6585..6611)	gp160 Epitope Map
Author Location	Env(120-128)
Epitope	KLTPLCVTL	Epitope Alignment
Epitope Name	Env120-128
Subtype	B
Species (MHC/HLA)	human(A*02:01)
Immunogen	peptide-HLA interaction
Country	United States
Experimental methods	Chromium-release assay
Keywords	enhancing activity

Notes

• Since HIV-1 infected peripheral dendritic cells (DCs) are functionally impaired in their role as antigen presenting cells (APCs), novel CTL responses in an asymptomatic HIV-patient were primed by using blood-derived DCs from healthy donors as APCs instead. Both epitope peptides and endogenously processed epitope antigen were now recognizable.
• CTL from an HLA-A*0201 positive subject did not react with this previously characterized peptide, KLTPLCVTL.

References

Dupuis1997 M. Dupuis, M. V. Peshwa, C. Benike, S.K> Kundu, E. G. Engleman, W. C. Van Schooten, and T. C. Merigan. Allogeneic Dendritic Cell Induction of HIV-Specific Cytotoxic T Lymphocyte Responses from T Cells of HIV Type 1-Infected and Uninfected Individuals. AIDS Res. Hum. Retroviruses, 13:33-39, 1997. The potential benefit of T cell-based vaccination for HIV-1 infection remains to be determined. Cytotoxic T lymphocytes (CTLs) appear to clear substantial populations of HIV-1 virus in vivo, although CTL activity may contribute to the decline in CD4+ T cell count observed in the course of the disease. To investigate further the role of specific CTL responses in the control of HIV-1 replication, we raised primary CTL lines against a panel of conserved HIV-1 epitopes using blood-derived dendritic cells as antigen-presenting cells (APCs). Specific primary human CTL responses were induced against HLA-A*0201-restricted peptides with dendritic cells from HIV-1-seronegative donors. This method of immunization elicited cytotoxic activities capable of recognizing endogenously processed antigen. The CTL induction protocol was extended in order to explore the capacity of HLA-matched allogeneic dendritic cells to evoke novel CTL responses in T cells from an HIV-seropositive asymptomatic individual. Allogeneic peptide-pulsed dendritic cells from a healthy sibling were capable of eliciting a CTL response directed against an HIV epitope (env814: SLLNATDIAV) that was initially not detected in the CTL effector population of the HIV-1- infected patient. The possibility of manipulating CTL specificity directed against multiple conserved HIV-1 epitopes represents a significant step in the evaluation of T cell-based vaccination for treatment of disease. PubMed ID: 8989425. Show all entries for this paper.

Displaying record number 58639

Download this epitope record as JSON.

HXB2 Location	gp160(813-822) gp41(302-311) DNA(8661..8690)	gp160 Epitope Map
Author Location	Env(814-823)
Epitope	SLLNATDIAV	Epitope Alignment
Epitope Name	Env814
Subtype	B
Species (MHC/HLA)	human(A*02:01)
Immunogen	peptide-HLA interaction, vaccine
Country	United States
Experimental methods	Chromium-release assay
Keywords	dendritic cells, enhancing activity

Vaccine Details

Notes

• Since HIV-1 infected peripheral dendritic cells (DCs) are functionally impaired in their role as antigen presenting cells (APCs), novel CTL responses in an asymptomatic HIV-patient were primed by using blood-derived DCs from healthy donors as APCs instead. Both epitope peptides and endogenously processed epitope antigen were now recognizable.
• CTL from an HLA-A*0201 positive subject did not react with previously characterized peptide SLLNATDIAV (Env814). Upon stimulation with a healthy sibling's DCs that had been primed with this peptide, however, the subject's CTL were able to mount a response to Env814 whether presented as (a) JY cells pulsed with Env814 or (b) APCs presenting Env814 after infection with recombinant vaccinia expressing HIV Env.

References

Dupuis1997 M. Dupuis, M. V. Peshwa, C. Benike, S.K> Kundu, E. G. Engleman, W. C. Van Schooten, and T. C. Merigan. Allogeneic Dendritic Cell Induction of HIV-Specific Cytotoxic T Lymphocyte Responses from T Cells of HIV Type 1-Infected and Uninfected Individuals. AIDS Res. Hum. Retroviruses, 13:33-39, 1997. The potential benefit of T cell-based vaccination for HIV-1 infection remains to be determined. Cytotoxic T lymphocytes (CTLs) appear to clear substantial populations of HIV-1 virus in vivo, although CTL activity may contribute to the decline in CD4+ T cell count observed in the course of the disease. To investigate further the role of specific CTL responses in the control of HIV-1 replication, we raised primary CTL lines against a panel of conserved HIV-1 epitopes using blood-derived dendritic cells as antigen-presenting cells (APCs). Specific primary human CTL responses were induced against HLA-A*0201-restricted peptides with dendritic cells from HIV-1-seronegative donors. This method of immunization elicited cytotoxic activities capable of recognizing endogenously processed antigen. The CTL induction protocol was extended in order to explore the capacity of HLA-matched allogeneic dendritic cells to evoke novel CTL responses in T cells from an HIV-seropositive asymptomatic individual. Allogeneic peptide-pulsed dendritic cells from a healthy sibling were capable of eliciting a CTL response directed against an HIV epitope (env814: SLLNATDIAV) that was initially not detected in the CTL effector population of the HIV-1- infected patient. The possibility of manipulating CTL specificity directed against multiple conserved HIV-1 epitopes represents a significant step in the evaluation of T cell-based vaccination for treatment of disease. PubMed ID: 8989425. Show all entries for this paper.